Nimobrain (Nimodipine)

Nimodipine, the active ingredient in Nimobrain, is a calcium channel blocker presented as an oral tablet for oral use. It selectively dilates cerebral arteries by inhibiting L‑type calcium channels, thereby reducing the risk of vasospasm and secondary ischemic injury after subarachnoid hemorrhage in adult patients.

GNH USA supplies Nimobrain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, transplant centres and oncology centres worldwide, ensuring consistent quality, regulatory compliance and reliable logistics through global critical care medicines.

Nimodipine is used to manage cerebral vasospasm, a complication of subarachnoid hemorrhage.

Prevention of cerebral vasospasm after subarachnoid hemorrhage: reduces the incidence of delayed ischemic neurological deficits.

Nimodipine may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Flushing: warm sensation with reddening of skin. - Nausea: occasional gastrointestinal upset. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, pruritus, or anaphylaxis. - Stevens‑Johnson syndrome: rare severe skin reaction. - Myocardial infarction: extremely rare cardiac event.

Before initiating therapy, clinicians should consider several safety measures.

Blood pressure monitoring: check regularly for hypotension. Hepatic function: avoid in severe liver impairment. Pregnancy: use only if potential benefit justifies risk. Drug interactions: review concomitant CYP3A4 inhibitors. Renal impairment: adjust dose in severe cases. Store at room temperature: keep in the original pack, protect from moisture.

Nimodipine can interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Grapefruit juice: can markedly raise drug concentration. - Other calcium channel blockers: additive vasodilatory effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce effectiveness. - Antihypertensive agents (beta‑blockers, ACE inhibitors): monitor for excessive blood pressure drop.